» Articles » PMID: 32848201

Evidence for Hypoxia Increasing the Tempo of Evolution in Glioblastoma

Overview
Journal Br J Cancer
Specialty Oncology
Date 2020 Aug 28
PMID 32848201
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Tumour hypoxia is associated with metastatic disease, and while there have been many mechanisms proposed for why tumour hypoxia is associated with metastatic disease, it remains unclear whether one precise mechanism is the key reason or several in concert. Somatic evolution drives cancer progression and treatment resistance, fuelled not only by genetic and epigenetic mutation but also by selection from interactions between tumour cells, normal cells and physical micro-environment. Ecological habitats influence evolutionary dynamics, but the impact on tempo of evolution is less clear.

Methods: We explored this complex dialogue with a combined clinical-theoretical approach by simulating a proliferative hierarchy under heterogeneous oxygen availability with an agent-based model. Predictions were compared against histology samples taken from glioblastoma patients, stained to elucidate areas of necrosis and TP53 expression heterogeneity.

Results: Results indicate that cell division in hypoxic environments is effectively upregulated, with low-oxygen niches providing avenues for tumour cells to spread. Analysis of human data indicates that cell division is not decreased under hypoxia, consistent with our results.

Conclusions: Our results suggest that hypoxia could be a crucible that effectively warps evolutionary velocity, making key mutations more likely. Thus, key tumour ecological niches such as hypoxic regions may alter the evolutionary tempo, driving mutations fuelling tumour heterogeneity.

Citing Articles

Comparative Clinical-Imaging and Histogenetic Analysis Between Astrocytoma IDH-Mutant Grade 4 and Glioblastoma IDH-Wildtype-Is There Really a Worse One?.

Orasanu C, Aschie M, Deacu M, Bosoteanu M, Vamesu S, Enciu M Diagnostics (Basel). 2025; 15(4).

PMID: 40002588 PMC: 11854731. DOI: 10.3390/diagnostics15040438.


Tumour hypoxia in driving genomic instability and tumour evolution.

Suvac A, Ashton J, Bristow R Nat Rev Cancer. 2025; 25(3):167-188.

PMID: 39875616 DOI: 10.1038/s41568-024-00781-9.


Hypoxia-induced one-carbon metabolic reprogramming in glioma stem-like cells.

He X, Wang J, Shi M, Liu C, Teng Z Life Med. 2025; 2(6):lnad048.

PMID: 39872059 PMC: 11749232. DOI: 10.1093/lifemedi/lnad048.


Research progress of drug resistance mechanism of temozolomide in the treatment of glioblastoma.

Wu H, Gao W, Chen P, Wei Y, Zhao H, Wang F Heliyon. 2024; 10(21):e39984.

PMID: 39568843 PMC: 11577240. DOI: 10.1016/j.heliyon.2024.e39984.


Spatial computational modelling illuminates the role of the tumour microenvironment for treating glioblastoma with immunotherapies.

Mongeon B, Hebert-Doutreloux J, Surendran A, Karimi E, Fiset B, Quail D NPJ Syst Biol Appl. 2024; 10(1):91.

PMID: 39155294 PMC: 11330976. DOI: 10.1038/s41540-024-00419-4.


References
1.
Yuan J, Narayanan L, Rockwell S, Glazer P . Diminished DNA repair and elevated mutagenesis in mammalian cells exposed to hypoxia and low pH. Cancer Res. 2000; 60(16):4372-6. View

2.
Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

3.
Rankin E, Nam J, Giaccia A . Hypoxia: Signaling the Metastatic Cascade. Trends Cancer. 2017; 2(6):295-304. PMC: 5808868. DOI: 10.1016/j.trecan.2016.05.006. View

4.
Yemelyanova A, Vang R, Kshirsagar M, Lu D, Marks M, Shih I . Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod Pathol. 2011; 24(9):1248-53. DOI: 10.1038/modpathol.2011.85. View

5.
Singh S, Hawkins C, Clarke I, Squire J, Bayani J, Hide T . Identification of human brain tumour initiating cells. Nature. 2004; 432(7015):396-401. DOI: 10.1038/nature03128. View